300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Paraguay
Seychelles
Botswana
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Angola
Europe
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Bangladesh
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
SPRIM Global Investments, VC Fund

SPRIM Global Investments

VC Fund

New York, United States

SPRIM Global Investments is a privately held investment company. SGI was established in 2008 following the global expansion of SPRIM Consulting & Services business.SPRIM Global Investments leverages the funnel of SPRIM’s sourcing, screening and selection processes across the globe to identify and invest in high potential health solutions. Wefind dynamic young companies proposing innovative offerings and help them to accelerate their growth. These startups can, in turn, leverage the SPRIM network, enabling them to fast-track their development. Our portfolio companies have full access to SPRIM’s fellow venture company experts across the globe as well as the company’s investment vehicles.

Total investments:
19
Last investment:
Lead investor:
89%

Last updated:

Industries SPRIM Global Investments invests in

BiotechnologyHealth CareMedical DevicePharmaceuticalTherapeutics

Stages SPRIM Global Investments invests in

Series ADebt FinancingVenture - Series UnknownSeedSeries B

Countries SPRIM Global Investments invests in

AustraliaUnited StatesFranceSwitzerlandItaly

Round sizes

Series A $10M–$22MDebt Financing $500k–$26M

Round size

Series A
$10M–$22M
Debt Financing
$500k–$26M

Investment Focus

Industry

  • Biotechnology 9 (47%)
  • Health Care 6 (32%)
  • Medical Device 4 (21%)
  • Pharmaceutical 4 (21%)
  • Therapeutics 3 (16%)
See all 14 industries →

Stage

  • Series A 5 (26%)
  • Debt Financing 3 (16%)
  • Venture - Series Unknown 2 (11%)
  • Seed 1 (5%)
  • Series B 1 (5%)
See all 10 stages →

Country

  • Australia 3 (16%)
  • United States 3 (16%)
  • France 2 (11%)
  • Switzerland 2 (11%)
  • Italy 1 (5%)
See all 8 countries →

Investments

CompanyDescriptionRoundLinks
Body Vision Medical Body Vision Medical
Body Vision Medical eliminates CT-to-body divergence and provides visual confirmation of tool-in-lesion prior to biopsy, while intraoperative CT imaging and enhanced fluoroscopy provide unparalleled control over diagnostic output. They can be a dedicated intraoperative 3D imaging solution for tool-in-lesion confirmation or a standalone navigationalbronchoscopy platform. Venture - Series Unknown / Aug 06, 2026
NinaMED NinaMED
NinaMED is a healthcare and medical solutions company associated with medical services and technology-enabled healthcare solutions. $10M / Seed / May 13, 2026
ErVimmune ErVimmune
ErVimmune creates novel immunotherapies that target non-conventional tumor antigens that are abnormally expressed in cancer cells and shared by tumors and patients, with a particular emphasis on meeting unmet medical requirements in cold malignancies. $19.9M / Series A / Jan 21, 2026
KAHR medical KAHR medical
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. $10M / Debt Financing / Oct 15, 2025
Vaxxas Vaxxas
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. $31.8M / Series D / Aug 25, 2025
Vaxxas Vaxxas
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. $25.9M / Debt Financing / Aug 25, 2025
Azalea Vision Azalea Vision
Azalea Vision is a medical manufacturer designing contact lenses with an active light management system for people with ocular disorders. $10.3M / Series A / Apr 29, 2025
RheumaGen RheumaGen
RheumaGen is a gene-editing technology developing therapeutics to cure rheumatoid arthritis. It offers an HLA gene-editing platform that uses stem-cell-enriched blood to alter DNA to suppress the immune system and stop rheumatoid arthritis's abnormal immune response. $15M / Series A / Jan 09, 2025
CILcare CILcare
CILcare specializes in providing drug solutions for hearing and ear disorders. $42M / Series A / Dec 04, 2024
Doron Therapeutics Doron Therapeutics
Doron Therapeutics is a clinical-stage biotechnology company that has developed intra-articular biologic drugs derived from placental tissue and consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective, and regenerative capabilities pivotal to the progressive and degenerative disease ofosteoarthritis. $11M / Series A / Nov 25, 2024
See all 19 investments →

Co-Investors

Afri Mobility 1 deal together
Aris Occitanie Aris Occitanie 1 deal together
Brandon Capital Brandon Capital 1 deal together
Business Asia Consultants 1 deal together
Crestone Crestone 1 deal together
OneVentures OneVentures 1 deal together

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Paraguay
Seychelles
Botswana
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Angola
Europe
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Bangladesh
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does SPRIM Global Investments invest in?

SPRIM Global Investments invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Debt Financing stage. Most of the 19 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is SPRIM Global Investments's check size?

SPRIM Global Investments typically joins rounds of $10M–$22M at Series A and $500k–$26M at Debt Financing. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SPRIM Global Investments participates in.

When did SPRIM Global Investments last invest?

The most recent investment recorded for SPRIM Global Investments closed in Aug 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
SPRIM Global Investments SPRIM Global Investments Find emails